DURECT Corporation (NASDAQ:DRRX) represented a move of -4.55 percent or $0.05 per share and closed its previous day trading session at $1.05. 520111 Shares were traded in the last trading session with an Average Volume of 669.13 Million Shares. The stock currently has a Market Capitalization of 155.96 Million.
Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.
The stock traded between $0.74 and $2.17 over 1-Year time period showing its price to sales ratio of 4.71. DURECT Corporation (NASDAQ:DRRX) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-2.53 and 200-Day Simple Moving Average of $-21.83. Its Price to Free Cash Flow is 0 and Price to Book of 15.
Analyst’s recommended the stock as 2.7 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, DURECT Corporation (NASDAQ:DRRX) reported its Actual EPS of $-0.04/share. The analysts offering Earnings Estimates for the company were believing that DURECT Corporation could bring EPS of $-0.06/share. The difference between Actual EPS and Estimated EPS was 0.02 Percent. Thus showing an Earnings Surprise of 33.3 Percent.
Egalet Corporation (NASDAQ:EGLT)
In the last trading session, Egalet Corporation (NASDAQ:EGLT) added its value by -0.94% closing at the price of $0.8. The stock currently has market capitalization of 37.09 Million, with average volume of 2.05 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Egalet Corporation (NASDAQ:EGLT) is showing beta of 0.51. This particular value of beta suggests that Egalet Corporation (NASDAQ:EGLT) has historically moved 51% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Egalet Corporation (NASDAQ:EGLT) is at $-3.39.
The stock currently has RSI of 36.56. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom.
Egalet Corporation (NASDAQ:EGLT) topped its 52-week high price of $5.600 on 03/29/17 and 52-Week Low Price of $0.770 on 02/14/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.72% and monthly volatility of 7.01% respectively.